Lupin signs exclusive licensing agreement for YUVEZZI in Europe

Lupin has announced that VISUfarma B.V. (VISUfarma), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited (Tenpoint).

Under the agreement, VISUfarma will hold exclusive rights to undertake regulatory activities, commercialisation, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75 per cent/0.1 per cent for the treatment of presbyopia in adults across the European Union, the United Kingdom, Switzerland, Norway and Iceland (Licensed Territories).

VISUfarma will make a strategic investment in Visus under the agreement. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.

Vinita Gupta, Chief Executive Officer, Lupin, said, “We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZI underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories.”

“This exciting partnership marks an important step for Tenpoint as we continue our work to make YUVEZZI available for the millions of patients with presbyopia and eye care professionals around the world,” said Henric Bjarke, Chief Executive Officer, Tenpoint. “Lupin’s strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma’s longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI to Europe.”

YUVEZZI is the first and only approved once-daily, dual-agent eye drop for presbyopia. The addition of YUVEZZI expands Lupin’s ophthalmology portfolio and supports its strategy to expand its specialty care business through therapies addressing patient needs.

Tenpoint is advancing the commercialisation of YUVEZZI in the United States following its U.S. FDA approval. Tenpoint has submitted an MMA in the UK through the MHRA’s International Recognition Procedure and will continue its plans for regulatory applications for YUVEZZI in other regions. 

The post Lupin signs exclusive licensing agreement for YUVEZZI in Europe appeared first on Express Pharma.